Mitsubishi Tanabe Pharma

Parkinson's Foundation Launches #ABCsOfPD Campaign for Parkinson's Awareness Month

Retrieved on: 
Tuesday, April 2, 2024
MTPA, Exercise, PD, Partnership, Advisory Council, Health, Mental health, Parkinson's Foundation, Parkinson's disease, Wellness, Mitsubishi Tanabe Pharma, Pharmaceutical industry

NEW YORK and MIAMI, April 2, 2024 /PRNewswire/ -- The Parkinson's Foundation honors Parkinson's Awareness Month with the launch of a new campaign, #ABCsOfPD .

Key Points: 
  • NEW YORK and MIAMI, April 2, 2024 /PRNewswire/ -- The Parkinson's Foundation honors Parkinson's Awareness Month with the launch of a new campaign, #ABCsOfPD .
  • "I'm happy and humbled to be raising awareness about the importance of exercise during Parkinson's Awareness Month," said Cindy Finestone, member of the Parkinson's Foundation People with Parkinson's Advisory Council.
  • The Parkinson's Foundation is also happy to announce their partnership with Mitsubishi Tanabe Pharma America (MTPA) this Parkinson's Awareness Month.
  • "This Parkinson's Awareness Month, we're proud to partner with the Parkinson's Foundation to help raise awareness and share important resources with the PD community."

Mitsubishi Chemical Group Corp Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs

Retrieved on: 
Friday, February 2, 2024
OLED, IBM, Partnership, Electronics, Mitsubishi Tanabe Pharma, IPS, Research, AI, Mitsubishi Chemical Corporation, Cloud computing, Environment, Mitsubishi Group, Patient, Engineering, IBM Quantum Experience, Keio University, Food, Information technology, Carbon, Investment, Clinical trial, MCHG, Capsule, Medicine, Acquisition, CFRP, Algorithm, ALS, Quantum, ICT, Retail

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- The "Mitsubishi Chemical Group Corporation - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 2, 2024 /PRNewswire/ -- The "Mitsubishi Chemical Group Corporation - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.
  • This report provides insight into Mitsubishi Chemical's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts.
  • Mitsubishi Chemical Group Corp (MCGC), formerly Mitsubishi Chemical Holdings Corp is a diversified chemical company.
  • MCGC also provides ethical pharmaceuticals, diagnostic reagents and instruments, capsules and pharmaceutical equipment, active pharmaceutical ingredients and intermediates, and self-health check services.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Orphan designation: Dersimelagon Treatment of erythropoietic protoporphyria, 16/03/2022 Positive

Retrieved on: 
Monday, December 18, 2023
Medicine, COMP, Prevalence, Update, European Commission, Trick or Treatment?, Mitsubishi Tanabe Pharma, Phototoxicity, EPP, Disease, Narcolepsy, EMA, Civil service commission, Patient, Agency, European, MC1R, Marketing, Committee, Pigment, Community, Diagnosis, Pain, No Date, No Signature, Erythropoietic protoporphyria, Skin, EURORDIS, Heerdt, Pharmaceutical industry, Medical device, Fine chemical

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of erythropoietic protoporphyria in the European Union on 16 March 2022.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
Tuesday, November 7, 2023
Molecule, Psychosis, Biomarker, Therapy, Rare, Biotechnology, Genetics, Psychiatry, Novo Nordisk, CNS, Deficit spending, Access, Mitsubishi Tanabe Pharma, Metabolism, Clinic, Lundbeck, Myenteric plexus, Lead candidate, Medicine, Drug discovery, Neurology, Maryland School, Cognitive deficit, University, Health, Brain, Roche, Kynurenine, Cognition, Pharmaceutical industry, Management, CIAS, Schizophrenia, Takeda, Pfizer, Series

NAARDEN, The Netherlands, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures. Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

Key Points: 
  • Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
  • Dr. Schwarcz pioneered the study of the kynurenine pathway in the brain, which established kynurenine’s substantive role in cognition and in the pathophysiology of schizophrenia.
  • Through the convergence of human genetics, biomarkers, and deep phenotyping, Kynexis is well-positioned to pursue a novel, precision psychiatry-based approach to develop KYN-5356 in CIAS.
  • Under the terms of the agreement, Kynexis has an exclusive worldwide license from MTPC to develop and commercialize KYN-5356 worldwide.

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 7, 2023
DLBCL, The Year's Best Science Fiction: Eleventh Annual Collection, MD Anderson Cancer Center, FDA, NSCLC, NYSE, PIN, University, IHC, S&M, EST, CD22, G&A, Mitsubishi Tanabe Pharma, Society, ASH, Environment, SOHO, Growth, ADC, Clinical trial, Follicular lymphoma, KAAG1, Rituximab, Pancreatic cancer, Lung cancer, Safety, Therapy, American Society of Pediatric Hematology/Oncology, Patient, Immunohistochemistry, AXL, Sarcoma, Bank, Pharmaceutical industry, Video game, Fine chemical, Camisole

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • Net product revenues were $14.3 million for the quarter ended September 30, 2023, compared to $21.3 million for the same quarter in 2022.
  • S&M expenses were $13.7 million for the quarter ended September 30, 2023, compared to $16.8 million for the same quarter in 2022.
  • G&A expenses were $9.4 million for the quarter ended September 30, 2023, compared to $19.6 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Mitsubishi Tanabe Pharma America Showcases Depth of ALS Research with Wide Range of Abstracts at 22nd Annual NEALS Meeting

Retrieved on: 
Wednesday, October 4, 2023
Real-World Evidence, Medical Affairs Bureau, Mitsubishi Tanabe Pharma, MGH, IDMC, MND, ALS, Research, NCRI, Mitsubishi Group, Biomarker, Data mart, Intravenous therapy, MTPA, CDM, Netherlands Institute for Sound and Vision, NHC, Survival, University Challenge 2013–14, Hospital, Patient, SVC, FDA, Massachusetts General Hospital, Disease, Pharmaceutical industry, Nursing, Edaravone, Safety, Optum

JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.

Key Points: 
  • JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.
  • Presentations include:
    A preliminary analysis of demographics and clinical characteristics in people with ALS being treated with RADICAVA ORS, utilizing U.S.-based administrative claims data from Optum's Clinformatics® Data Mart (CDM), will be presented.
  • REFINE-ALS is a NEALS-affiliated clinical trial sponsored by MTPA and conducted in collaboration with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH).
  • Real-World Survival Effectiveness of Edaravone in Amyotrophic Lateral Sclerosis: A Propensity Score Weighted, Registry-based, Canada-wide Cohort Study
    Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis

Canadian-Developed AI Technology Aims to Support Early Detection of ALS

Retrieved on: 
Wednesday, September 20, 2023
Mitsubishi Tanabe Pharma, Process, Neurodegenerative disease, Health information management, EMG, Steering, ALS, Cerner, Neurology, Progress, Neuro-oncology, Neuro, Committee, Patient, Amyotrophy, Artificial intelligence, Diagnosis, AI, Disease, Nursing, Medical device

"Early diagnosis and treatment of ALS can improve outcomes, but the disease can be difficult to diagnose in its early stages.

Key Points: 
  • "Early diagnosis and treatment of ALS can improve outcomes, but the disease can be difficult to diagnose in its early stages.
  • "Process for Progress in ALS is a unique advancement in AI medical technology which can help HCPs identify patients who present multiple warning signs for ALS so that they can receive expedited follow-ups, diagnoses, and treatment if needed."
  • "We are proud to support the introduction of this important AI technology as part of our long-standing commitment to leading scientific innovation, collaborating with HCPs, and working tirelessly to meet the needs of the ALS community."
  • For more information on Process for Progress in ALS: An EMR-based practice enhancement initiative, please visit: https://www.alsprogress.ca .

MITSUBISHI TANABE PHARMA CANADA ANNOUNCES COLLABORATION WITH THE CNDR ON FIRST CANADIAN REAL-WORLD EVIDENCE STUDY OF RADICAVA® IV (EDARAVONE) SURVIVAL BENEFITS IN ALS

Retrieved on: 
Wednesday, August 9, 2023
Mitsubishi Tanabe Pharma, Medical Affairs Bureau, University, Edaravone, ALS, Neurodegenerative disease, Survival, ALS Society of Canada, Brain, Research, Congress, Patient, Frontotemporal dementia, C9ORF72, Diagnosis, Rare, News, Caregiver, Sunnybrook Health Sciences Centre, Disease, Pharmaceutical industry, Dentistry

"The objective of this study is to describe real-world survival effectiveness over a longer timeframe."

Key Points: 
  • "The objective of this study is to describe real-world survival effectiveness over a longer timeframe."
  • "Access to innovative therapies is an urgent issue for people living with ALS," said Tammy Moore, President, ALS Canada.
  • The retrospective cohort study includes patients with ALS across Canada with a minimum six-month RADICAVA® IV exposure between 2017 and 2022.
  • The impact of edaravone on survival in patients with ALS has not been established and is the subject of the real-world evidence collaboration with CNDR.